- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 30
The Center for Biosimilars® recaps the top stories for the week of September 30, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 30, 2019.
Number 5: A new report from the House Ways and Means Committee finds that Americans pay nearly 4 times more for drugs than do patients in other countries.
Number 4: During the week’s European Society for Medical Oncology Congress 2019, a research team presented findings from a phase 3 trial of Samsung Bioepis' proposed bevacizumab biosimilar.
Number 3: New research suggests that state-level drug price transparency laws are largely ineffective at revealing true transaction prices.
Number 2: A newly introduced item of legislation proposes to eliminate co-payments for patients when they receive biosimilars in Medicare Part B.
Number 1: Pfizer says that it will launch its bevacizumab biosimilar, Zirabev, in the United States on December 31.
Finally, last week, our e-newsletter asked whether you think that biosimilars of rituximab will make treatment more accessible for patients with neurological diseases like multiple sclerosis.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.
